IN2015DN00515A - - Google Patents

Info

Publication number
IN2015DN00515A
IN2015DN00515A IN515DEN2015A IN2015DN00515A IN 2015DN00515 A IN2015DN00515 A IN 2015DN00515A IN 515DEN2015 A IN515DEN2015 A IN 515DEN2015A IN 2015DN00515 A IN2015DN00515 A IN 2015DN00515A
Authority
IN
India
Prior art keywords
microglobulin
alpha
treatment
relates
present
Prior art date
Application number
Other languages
English (en)
Inventor
Bo Akerström
Magnus Gram
Lena Rosenlöf
Original Assignee
A1M Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma Ab filed Critical A1M Pharma Ab
Publication of IN2015DN00515A publication Critical patent/IN2015DN00515A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722Plasma globulins, lactoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
IN515DEN2015 2012-09-05 2013-09-04 IN2015DN00515A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201270538 2012-09-05
DKPA201270557 2012-09-12
PCT/EP2013/068270 WO2014037390A1 (fr) 2012-09-05 2013-09-04 Alpha-1-microglobuline destinée à être utilisée dans le traitement de maladies associées aux mitochondries

Publications (1)

Publication Number Publication Date
IN2015DN00515A true IN2015DN00515A (fr) 2015-06-26

Family

ID=49162118

Family Applications (1)

Application Number Title Priority Date Filing Date
IN515DEN2015 IN2015DN00515A (fr) 2012-09-05 2013-09-04

Country Status (22)

Country Link
US (1) US10226507B2 (fr)
EP (1) EP2900254B1 (fr)
JP (2) JP2015533790A (fr)
KR (1) KR20150047510A (fr)
CN (1) CN104661673A (fr)
AU (1) AU2013311714C1 (fr)
BR (1) BR112015003957A2 (fr)
CA (1) CA2881321A1 (fr)
DK (1) DK2900254T3 (fr)
EA (1) EA028963B1 (fr)
ES (1) ES2599034T3 (fr)
HK (1) HK1210585A1 (fr)
HR (1) HRP20161364T1 (fr)
HU (1) HUE030559T2 (fr)
IN (1) IN2015DN00515A (fr)
MX (1) MX357656B (fr)
NZ (1) NZ629621A (fr)
PL (1) PL2900254T3 (fr)
PT (1) PT2900254T (fr)
SG (1) SG11201500669SA (fr)
WO (1) WO2014037390A1 (fr)
ZA (1) ZA201500547B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016204360A (ja) * 2015-02-25 2016-12-08 エー1エム ファーマ エービーA1M Pharma AB 放射性核種療法における腎臓の保護に用いるためのアルファ−1−ミクログロブリン
KR20180116385A (ko) * 2016-02-25 2018-10-24 에이원엠 파마 에이비 조영제의 사용과 관련하여 신장 보호에서 이용하기 위한 알파-1-마이크로글로불린
CN108779157B (zh) 2016-03-18 2022-12-30 卫士医疗国际公司 新α-1-微球蛋白衍生蛋白及其应用
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
CN110452980B (zh) * 2019-09-23 2023-07-28 武汉儿童医院 一种线粒体脑肌病诊断试剂盒及应用
US20220362293A1 (en) * 2019-09-25 2022-11-17 Cytegen Corp. Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products
CN115575646B (zh) * 2022-11-21 2023-04-28 四川大学华西医院 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882331A (zh) * 2003-11-26 2006-12-20 塞诺菲-安万特德国有限公司 作为心血管风险升高指示剂的肾小管性蛋白尿
EA022609B1 (ru) * 2007-02-12 2016-02-29 А1М Фарма Аб Применение свободного фетального гемоглобина в качестве маркера преэклампсии
PT2300614E (pt) * 2008-02-04 2016-03-02 Yissum Res Dev Co Métodos e composições para tratamento de distúrbios mitocondriais
EP2313106B1 (fr) * 2008-07-18 2016-03-30 A1M Pharma AB Utilisation médicale du piégeur de radical et antioxydant alpha-1-microglobuline

Also Published As

Publication number Publication date
DK2900254T3 (en) 2016-08-29
ZA201500547B (en) 2017-09-27
AU2013311714A1 (en) 2015-03-12
US20150258171A1 (en) 2015-09-17
EP2900254B1 (fr) 2016-08-03
HK1210585A1 (en) 2016-04-29
JP2015533790A (ja) 2015-11-26
US10226507B2 (en) 2019-03-12
ES2599034T3 (es) 2017-01-31
CN104661673A (zh) 2015-05-27
PL2900254T3 (pl) 2017-02-28
WO2014037390A1 (fr) 2014-03-13
AU2013311714C1 (en) 2018-01-25
EA028963B1 (ru) 2018-01-31
AU2013311714B2 (en) 2017-10-12
NZ629621A (en) 2015-09-25
JP2018203756A (ja) 2018-12-27
BR112015003957A2 (pt) 2017-08-08
MX2015002604A (es) 2015-06-10
SG11201500669SA (en) 2015-02-27
HUE030559T2 (en) 2017-05-29
HRP20161364T1 (hr) 2016-12-16
CA2881321A1 (fr) 2014-03-13
PT2900254T (pt) 2016-10-18
EP2900254A1 (fr) 2015-08-05
EA201590503A1 (ru) 2015-06-30
KR20150047510A (ko) 2015-05-04
MX357656B (es) 2018-07-18

Similar Documents

Publication Publication Date Title
IN2015DN00515A (fr)
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
MX2021004211A (es) Composiciones vacuna.
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
EP2822558A4 (fr) Activation de procaspase 3 par polythérapie
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
IL235429A0 (en) (r)-nifortal, its use in the treatment of infections and the preparation of (r) and (s)-nifortal
HK1215794A1 (zh) 用於治療疾病的同種異體自噬體富集組合物
EP2825194A4 (fr) Utilisation d'antithrombine dans le traitement de la pré-éclampsie
GB2518801B (en) Improvements in, or relating to, caskets or coffins
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
IN2014KN01772A (fr)
ZA201500652B (en) Medicine againts gastroesephageal reflux disease
BR112015023730A2 (pt) uso de sedoeptulose como suplemento nutricional
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
GB201310748D0 (en) Student's clinic
UA24322S (uk) Стамеска пасічника
FI20115180L (fi) Koostumus käytettäväksi sairauden hoidossa
UA75904U (xx) Стоматологічний комплект "sadaf dent streg"
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
IN2012DE01204A (en) "shikhar technology"
MX2015001134A (es) Compuestos terapeuticos.